# A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

> **NCT05329623** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 33 (actual)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** JDQ443

## Key facts

- **NCT ID:** NCT05329623
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-03
- **Primary completion:** 2024-04-07
- **Final completion:** 2024-04-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05329623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05329623, "A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05329623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*